Defunct Company
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
363
NCT06472245
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Phase: Phase 3
Role: Collaborator
Start: Dec 3, 2024
Completion: Dec 15, 2028